Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVB103 in neovascular age-related macular degeneration
CTR20244398Phase 2Active
- Sponsor
- InnoVec Biotherapeutics
- Start
- Nov 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of IVB103 in exudative macular degeneration, sponsored by InnoVec Biotherapeutics. Started Nov 2024; status: active.
02
Drugs
IVB103
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20244398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244398.